Abstract 1820: Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer (PROC).
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: Daiichi Sankyo (United States)
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148635859
Cites:
Cited by:
Related to: